Clinical Trials to Treat Adult Glioblastoma

Trials 1-16 of 16
  • Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma

    This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
    Location: 164 locations

  • An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

    The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving Nivolumab in addition to temozolomide plus radiation therapy.
    Location: 15 locations

  • Terameprocol in Treating Patients with Recurrent High Grade Glioma

    This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 7 locations

  • Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients with Newly Diagnosed or Recurrent Glioblastoma

    This phase I trial studies the side effects and best dose of adavosertib when given together with radiation therapy and temozolomide in treating patients with newly diagnosed or glioblastoma that has come back. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed or recurrent glioblastoma.
    Location: 12 locations

  • A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

    This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with oral veledimex.
    Location: 5 locations

  • Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

    This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors. Using a preclinical glioblastoma model, it was recently shown that adding IDO-blocking drugs to temozolomide plus radiation significantly enhanced survival by driving a vigorous, tumordirected inflammatory response. This data provided the rationale for the companion adult phase 1 trial using indoximod (IND#120813) plus temozolomide to treat adults with glioblastoma, which is currently open (NCT02052648). The goal of this pediatric study is to bring IDO-based immunotherapy into the clinic for children with brain tumors. This study will provide a foundation for future pediatric trials testing indoximod combined with radiation and temozolomide in the up-front setting for patients with newly diagnosed central nervous system tumors.
    Location: Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia

  • Temozolomide and Targeted or Standard Brain Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme

    This randomized phase II trial studies how well an increased dose of radiation therapy applied to a specific part of the brain works compared to standard radiation therapy when given with temozolomide in treating patients with a newly diagnosed brain tumor, such as glioblastoma multiforme. The brain contains cells called neural progenitor cells (NPC) that may be important in the brain’s response to injury but may also contribute to tumor recurrence. Subventricular zone radiation therapy targeting these cells may improve the local control and delay the brain tumor from coming back. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether subventricular zone radiation therapy and temozolomide are more effective than standard radiation therapy and temozolomide in treating patients with glioblastoma multiforme.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Low-Dose Whole-Brain Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

    This phase II trial studies the side effects and how well low-dose whole-brain radiation therapy and temozolomide work in treating patients with newly diagnosed glioblastoma multiforme. Radiation therapy uses high-energy x-rays to kill tumor cells. Low-dose whole-brain radiation therapy may kill the microscopic tumor cells which are outside of the area of the brain that receives partial brain radiation therapy. Drugs used in chemotherapy, such as temozolomide, work to stop the growth of tumor cells by killing the cells. Giving low-dose whole-brain radiation therapy with temozolomide may kill more tumor cells.
    Location: University of Maryland / Greenebaum Cancer Center, Baltimore, Maryland

  • Lapatinib Ditosylate, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme

    This phase II clinical trial studies the side effects and to see how well it works when giving lapatinib ditosylate, temozolomide, and radiation therapy together in treating patients with newly diagnosed glioblastoma multiforme. Lapatinib ditosylate may top the growth of tumor cells by blocking some of the enzymes needed for cell growth. Temozolomide may slow the growth of tumor cells. Radiation therapy uses high energy beams to kill tumor cells and shrink tumor. Giving lapatinib ditosylate, temozolomide, and radiation therapy together may be a better treatment for patients with newly diagnosed glioblastoma multiforme.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Genetically Modified T Cells in Treating Patients with Malignant Gliomas

    This phase I / II trial studies the side effects and best dose of genetically modified T cells and to see how well they work in treating patients with malignant gliomas. Placing a gene that has been created in the laboratory into white blood cells may help the body build an immune response to kill tumor cells.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Mibefradil Dihydrochloride and Hypofractionated Radiation Therapy in Treating Patients with Progressive or Recurrent Glioblastoma Multiforme

    This phase I trial studies the side effects and best dose of mibefradil dihydrochloride when given together with hypofractionated radiation therapy in treating patients with glioblastoma multiforme that is growing, spreading, or getting worse (progressive), or has come back (recurrent). Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Mibefradil dihydrochloride may also make tumor cells more sensitive to radiation therapy. Hypofractionated radiation therapy is a radiation treatment in which the total dose of radiation is divided into large doses over a shorter period of time. Giving mibefradil dihydrochloride with hypofractionated radiation therapy may be a better treatment for patients with glioblastoma multiforme.
    Location: Yale University, New Haven, Connecticut

  • Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

    This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
    Location: See Clinical Trials.gov

  • AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

    Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.
    Location: See Clinical Trials.gov

  • EGFRBi-Armed Autologous T Cells in Treating Patients with Recurrent or Refractory Glioblastoma

    This phase I / II trial studies the side effects and best dose of epidermal growth factor receptor bispecific antibody (EGFRBi)-armed autologous T cells and how well it works in treating patients with glioblastoma that have come back or does not respond to treatment. EGFRBi-armed autologous T cells coated with antibodies (proteins used by the immune system to target and kill foreign objects such as cancer cells) may have great ability to seek out, attach to, and destroy glioblastoma cells.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Akt / ERK Inhibitor ONC201 in Treating Patients with Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of Akt / ERK inhibitor ONC201 in treating patients with solid tumors that have spread to other anatomic sites or is no longer responding to treatment. Akt / ERK inhibitor ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

    This phase I trial is studying the side effects and best dose of nelfinavir mesylate (NFV) when given together with radiation therapy and temozolomide in treating patients with glioblastoma multiforme. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving nelfinavir mesylate together with radiation therapy and temozolomide may kill more tumor cells.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania